Navigation Links
NUCRYST appoints interim CEO
Date:1/19/2009

PRINCETON, NJ, Jan. 19 /PRNewswire-FirstCall/ - The Board of Directors of NUCRYST Pharmaceuticals Corp. today announced the appointment of David B. Holtz as interim President and Chief Executive Officer of the Company and Neil Carragher as Chairman, effective immediately. Mr. Holtz replaces Thomas E. Gardner, who was Chairman, President and Chief Executive Officer. Mr. Carragher, currently lead director of NUCRYST, will assume the role of Chairman, effective immediately. Mr. Holtz will also remain as CFO.

Previously, Mr. Holtz was Vice President and Chief Financial Officer of NUCRYST.

"David's experience and skills will be beneficial to NUCRYST as management focuses all efforts on bringing the company to profitability," said Mr. Carragher. "We thank Tom Gardner for his many contributions to the company and for his dedicated service."

Before joining NUCRYST, Mr. Holtz served as a financial management consultant for various start-up companies, including Virium Pharmaceuticals, Inc. Previously he worked in managerial roles of increasing importance at Integra LifeSciences Holdings Corporation from October 1993 through December 2006, most recently as Senior Vice President Finance. While at Integra, Mr. Holtz oversaw Integra's European operations to support the transition of acquisitions in Europe and managed all worldwide financial reporting and accounting functions. Prior to Integra, he worked for Coopers & Lybrand LLP and Cono Leasing Corporation. Mr. Holtz received a B.S. in Business Administration with an emphasis on finance from Susquehanna University.

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed wor
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NUCRYST Pharmaceuticals appoints a new director
2. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
3. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
4. NUCRYST Receives Deficiency Notice from NASDAQ
5. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
6. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
7. NUCRYST Announces First Quarter 2008 Financial Results
8. NUCRYST Announces Management Realignment and R&D Portfolio Change
9. NUCRYST Announces Senior Management Change
10. NUCRYST Pharmaceuticals announces year-end results
11. NUCRYST Pharmaceuticals announces 2007 third quarter results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... -- U.S. heart experts recommend doctors use a 14-point ... people for underlying heart disease that could result in ... the American College of Cardiology said in a joint ... history along with a physical examination can help identify ... risks for sudden cardiac death. The statement, ...
(Date:9/15/2014)... 2014 “Canada Gynecological Devices Market ... the Canada Gynecological Devices market. The report provides ... units) and average prices (in US dollars) within ... Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical ... Endometrial Ablation Devices (Thermal Balloon, Hydrothermal Ablation ...
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. ... twice as often as they,re actually needed for children ... More than 11 million antibiotic prescriptions written each ... to researchers from University of Washington and Seattle Children,s ... eradicate children,s viral illnesses, researchers said, but supports the ...
(Date:9/15/2014)... 15, 2014 As Colorado's historic ... its first full year, there are a variety ... in the evolution of its marketing and branding. ... taken by Denver's Kindman, one of the state's ... , Kindman has pioneered the first-ever branded and ...
(Date:9/15/2014)... Physicians and clinicians from around ... at the Lowes Coronado Bay Resort for the ... . This CME accredited medical conference ... healthcare professionals—about the nutritional science that overwhelmingly supports ... its proven ability to prevent, suspend and, often, ...
Breaking Medicine News(10 mins):Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 2Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 3Health News:Canada Gynecological Devices Market Outlook to 2020 in New Report Available at MarketOptimizer.org 4Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 2Health News:San Diego Plays Host This Week to International Plant-based Nutrition Healthcare Conference Featuring Drs. Ornish, Esselstyn, Campbell and Other Leading Experts 3
... It,s long been known that obesity increases diabetes risk, but ... someone carries -- and how long it,s carried -- can ... the growing number of obese children and teens who will ... researchers from the University of Michigan Health System warn in ...
... 2011) More part-time employment for surgeons, particularly retiring older ... families, may considerably reduce the surgeon shortage in the United ... September issue of the Journal of the American College ... gaining popularity among Generation X (currently ages 30 through early ...
... HealthDay Reporter , SUNDAY, Sept. 11 (HealthDay News) -- ... of Pearl Harbor still packs a psychological punch for many ... serves as the moment when a stunned young country shed ... stage with the now-iconic can-do bravado of the "Greatest Generation." ...
... The Journal of Emergency Medical Services (JEMS) today announces ... featuring first-person accounts of responders who were thrust into ... when terrorists invaded their response districts and their ... responders throughout the world, think, train, respond and live ...
... FRIDAY, Sept. 9 (HealthDay News) -- Almost half of all ... the months following the 9/11 terrorist attacks still struggle with ... Harris Interactive/HealthDay poll found. The most common ... 24 percent of those still affected, and anxiety, by 13 ...
... , ROCHESTER, Minn. -- Mayo Clinic researchers have developed a ... to combat human HIV/AIDS and other diseases. The goal is ... virus. The findings -- called fascinating and landmark by one ... Nature Methods . Feline immunodeficiency ...
Cached Medicine News:Health News:Lifetime 'Dose' of Excess Weight Linked to Diabetes Risk 2Health News:Allowing part-time surgeons may help address workforce shortage 2Health News:9/11 Left Permanent Scars on the American Psyche 2Health News:9/11 Left Permanent Scars on the American Psyche 3Health News:9/11 Left Permanent Scars on the American Psyche 4Health News:9/11 Left Permanent Scars on the American Psyche 5Health News:9/11 Left Permanent Scars on the American Psyche 6Health News:Out of the darkness 2Health News:For Many Americans, 9/11 Worries Still Dominate 2Health News:For Many Americans, 9/11 Worries Still Dominate 3Health News:Mayo Clinic teams with glowing cats against AIDS, other diseases 2
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... "Closed Drug Transfer Systems to 2020" report to ... deemed hazardous to humans has been receiving increasing amounts ... these substances become more clearly understood. For caregivers and ... forefront of attempts to mitigate exposure to cytotoxic drugs ...
Breaking Medicine Technology:First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3
... Doubled Time to Progression and Overall Response Rate as ... in Patients with 2nd or 3rd Line Metastatic Colon ... KERX ) today announced data on the ... cancer, in combination with capecitabine as a treatment for ...
... increase the risk of breast cancer recurrence , ... found that taking tamoxifen with certain antidepressants more than ... taking both medications. The antidepressants inhibit an enzyme, CYP2D6, ... ) , , The study ...
Cached Medicine Technology:Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: